FRM
BCAB

Fox Run Management’s BIOATLA INC BCAB Stock Holding History

Fox Run Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-510
Closed -$210K – 659
2022
Q4 		$210K Buy
+510
New +$212K 0.08% 474

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fox Run Management's BCAB Position: Q1 2023 in Review

Fox Run Management sold out of BIOATLA INC (BCAB) in Q1 2023, closing a stake of 510 shares — an estimated $210K sold.

Fox Run Management first reported a position in BCAB in Q4 2022 and held it in 1 quarter. The position peaked at $210K in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • Fox Run Management reported no remaining BIOATLA INC position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 510 BIOATLA INC shares in Q1 2023, an estimated $210K.
  • Fox Run Management first reported a position in BIOATLA INC in Q4 2022 and held it in 1 quarter.
  • Fox Run Management's BIOATLA INC position peaked at $210K in Q4 2022.
  • 79 funds tracked by Wall St. Rank held BIOATLA INC as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.